OTLC vs QNCX: Which is Better to Buy in 2026?

Side-by-side fundamental comparison based on AI analysis of SEC filings

AI Verdict

QNCX has stronger fundamentals based on our AI analysis.

OTLC
Oncotelic Therapeutics, Inc.
STRONG SELL
95%
Confidence
VS
QNCX
Quince Therapeutics, Inc.
STRONG SELL
97%
Confidence

OTLC vs QNCX Fundamental Comparison

Metric OTLC QNCX
Revenue $70,000.0 N/A
Net Income $-1.1M $-84.0M
Net Margin -1,526.0% N/A
ROE -11.8% N/A
ROA -3.8% -89.8%
Current Ratio 0.08x 0.53x
Debt/Equity 0.14x N/A
EPS $0.00 $-1.68

Green = Better metric | Red = Weaker metric

View Full OTLC Analysis →
View Full QNCX Analysis →
Browse Sectors: Technology Healthcare Finance Energy Consumer Industrial
Stock Lists: Strong Buy Undervalued Growth Dividend

You Might Also Compare

OTLC vs AAPL QNCX vs MSFT OTLC vs GOOGL QNCX vs AMZN

OTLC vs QNCX: Frequently Asked Questions

Is OTLC or QNCX a better buy in 2026?

Based on dual AI fundamental analysis (Claude and ChatGPT), QNCX has stronger fundamentals. OTLC is rated STRONG SELL (95% confidence) while QNCX is rated STRONG SELL (97% confidence). This is not investment advice.

How does OTLC compare to QNCX fundamentally?

Oncotelic Therapeutics, Inc. has ROE of -11.8% vs Quince Therapeutics, Inc.'s N/A. Net margins are -1,526.0% vs N/A respectively.

Which stock pays higher dividends, OTLC or QNCX?

OTLC has a dividend yield of N/A or no dividend while QNCX has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.

Should I invest in OTLC or QNCX for long term?

For long-term investing, consider that OTLC has STRONG SELL rating with 95% confidence, while QNCX has STRONG SELL rating with 97% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.

What do the AI models say about OTLC vs QNCX?

Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For OTLC vs QNCX, the AI consensus favors QNCX based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.